ArticleLeukemia2018

Oncogenic activation of JAK3-STAT signaling confers clinical sensitivity to PRN371, a novel selective and potent JAK3 inhibitor, in natural killer/T-cell lymphoma.

M -L Nairismägi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.